Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | GRM5 | P41594 | 5/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353809 | 0.79 | KDM6B (0.37) | EPHX2GRM5ALDH1A1 | |
| SCHEMBL3353814 | 0.79 | KDM6B (0.37) | EPHX2GRM5ALDH1A1 | |
| SCHEMBL4497890 | 0.76 | CREBBP (0.39) | EPHX2GRM5ALDH1A1HPGD | |
| SCHEMBL4497895 | 0.74 | SYK (0.35) | EPHX2GRM5ALDH1A1 | |
| SCHEMBL4497897 | 0.74 | SYK (0.35) | EPHX2GRM5ALDH1A1 | |
| SCHEMBL4509518 | 0.74 | ACACB (0.42) | — | |
| SCHEMBL1286119 | 0.73 | THRA (0.36) | EPHX2GRM5ALDH1A1MAPTHPGD | |
| SCHEMBL3353299 | 0.71 | GRM5 (0.34) | EPHX2GRM5ALDH1A1 | |
| SCHEMBL4585945 | 0.71 | OPRK1 (0.32) | GRM5 | |
| SCHEMBL11641867 | 0.70 | ESR1 (0.44) | ALDH1A1MAPTHPGDSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834007-B2 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049577-A1 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049577-A1 | CGRP antagonists | CALCRL, CALCR, CALCA | EPHX2 2085/4885GRM5 365/4885AR 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.